Dow Rallies on Positive Vaccine News; Tech Jumps


© Reuters.

By Yasin Ebrahim

Investing.com – The Dow rallied Monday, led by tech as deal-making activity and positive vaccine news prompted bullish bets on stocks.

The rose 1.18%, or 326 points. The was up 1.26%, while the added 1.87%.

The tech-heavy Nasdaq snapped its two-day losing streak as deal activity lifted sentiment on the sector.

Oracle Corporation (NYSE:) jumped 4% as the company appears to be at the front of the queue to partner with ByteDance’s TikTok business in the U.S. ByteDance reportedly said it prefers to partner, rather than sell, TikTok’s U.S. business, rejecting an offer from Microsoft Corporation.

U.S. Treasury Secretary Steven Mnuchin confirmed the Trump administration has received the proposal offer from Oracle for TikTok ahead of a deadline this week.

Microsoft (NASDAQ:) ended 0.6% higher, while other names making up the Fab 5, which accounts for 25% of the S&P 500, also ended mostly lower. Apple Inc (NASDAQ:)  was up more than 1%, while Facebook (NASDAQ:), Alphabet (NASDAQ:) and Amazon.com (NASDAQ:), ended in the red.

In chip stocks, Nvidia (NASDAQ:) rallied 6% after it announced a multi-billion acquisition of chip licensing company ARM holdings. The company also received a price upgrade from Jefferies (NYSE:) to a street-high $680 from $570.

Micron Technology (NASDAQ:) also pushed chip stocks higher, rising 6% after Goldman Sachs (NYSE:) upgraded the stock to buy from neutral, citing strong management execution.

Investor sentiment was also supported by positive vaccine news after AstraZeneca PLC (LON:) resumed its Covid-19 vaccine trial in the U.K. Trials in the South Africa, Brazil and the U.S. remain on pause. Trials of the vaccine candidate are expected to resume midweek in the U.S.    

READ  Dealmakers eye cross-border M&A recovery as mega mergers roll on

Vaxart (NASDAQ:) jumped 47% after receiving clearance from the U.S. Food and Drug Administration to start human trials of its Covid-19 vaccine candidate

In other news, Gilead tabled a $21 billion offer for Immunomedics to bolster its portfolio of oncology drugs. Gilead Sciences Inc (NASDAQ:) was up more than 2%, while Immunomedics (NASDAQ:) surged 98%.   

Nikola Corp (NASDAQ:) pared some of its losses from last week, rising nearly 12% as the electric pickup maker continued to hit back at allegations of fraud published in a report last week from short-seller Hindenburg.

“The report was designed to provide a false impression to investors and to negatively manipulate the market in order to financially benefit short sellers, including Hindenburg itself,” Nikola said in a statement.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

READ  France considering bailout for Air France-KLM - Les Echos





READ SOURCE

LEAVE A REPLY

Please enter your comment!
Please enter your name here